IL137146A0 - Hydroxamic and carboxylic acid derivatives - Google Patents

Hydroxamic and carboxylic acid derivatives

Info

Publication number
IL137146A0
IL137146A0 IL13714699A IL13714699A IL137146A0 IL 137146 A0 IL137146 A0 IL 137146A0 IL 13714699 A IL13714699 A IL 13714699A IL 13714699 A IL13714699 A IL 13714699A IL 137146 A0 IL137146 A0 IL 137146A0
Authority
IL
Israel
Prior art keywords
hydroxamic
carboxylic acid
acid derivatives
receptors
tnf
Prior art date
Application number
IL13714699A
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802073.8A external-priority patent/GB9802073D0/en
Priority claimed from GBGB9819574.6A external-priority patent/GB9819574D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of IL137146A0 publication Critical patent/IL137146A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

For the treatment of cancer, inflammation, and other conditions associated with matrix metalloproteinases or that are mediated by TNF alpha or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-1 receptors, or IL-6 receptors, disclosed are compounds of the general formula B-X-(CH2)m-(CR1R2)n-W-COY.
IL13714699A 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives IL137146A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9802073.8A GB9802073D0 (en) 1998-01-30 1998-01-30 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9819574.6A GB9819574D0 (en) 1998-09-08 1998-09-08 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
PCT/GB1999/000313 WO1999038843A1 (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives
US09/239,603 US6100266A (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives

Publications (1)

Publication Number Publication Date
IL137146A0 true IL137146A0 (en) 2001-07-24

Family

ID=27269200

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13714699A IL137146A0 (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives

Country Status (18)

Country Link
US (1) US6100266A (en)
EP (1) EP1051395B1 (en)
JP (1) JP2002501943A (en)
CN (1) CN100402496C (en)
AT (1) ATE346041T1 (en)
AU (1) AU735929B2 (en)
BR (1) BR9908215A (en)
CA (1) CA2317455C (en)
CY (1) CY1106338T1 (en)
DE (1) DE69934094T2 (en)
DK (1) DK1051395T3 (en)
ES (1) ES2277424T3 (en)
HK (1) HK1029330A1 (en)
HU (1) HUP0100597A3 (en)
IL (1) IL137146A0 (en)
NO (1) NO326266B1 (en)
PL (1) PL200418B1 (en)
WO (1) WO1999038843A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
NZ515829A (en) 1999-06-04 2003-10-31 Astrazeneca Ab Inhibitors of metalloproteinases
JP2003519119A (en) * 1999-12-24 2003-06-17 スミスクライン ビーチャム パブリック リミテッド カンパニー (Hetero) bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives
AU2001232113A1 (en) * 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
RU2283306C2 (en) 2000-02-21 2006-09-10 Астразенека Аб Piperidine- and piperazine-substituted n-hydroxyformamides as inhibitors of metalloproteinases
US20040024066A1 (en) * 2000-05-25 2004-02-05 Best Desmond John Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
FR2827859B1 (en) * 2001-07-30 2005-09-23 Lipha 4- (ARYLTHIO) - OR 4- (HETEROARYLTHIO) -BUTYRIC DERIVATIVES IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DIABETES
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119474D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
WO2003022801A1 (en) 2001-09-07 2003-03-20 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
GB0128378D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
GB0128376D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel compounds
SE0301922D0 (en) * 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
AU2006316552B2 (en) * 2005-11-24 2012-06-07 Merck Serono Sa N-hydroxyamide derivatives and use thereof
DK2041181T3 (en) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specific protease inhibitors and their use in cancer therapy
CA2804918C (en) 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
WO1997049679A1 (en) * 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
ID21897A (en) * 1996-09-27 1999-08-05 Upjohn Co ACID B-SULFONYL HYDROXYCAMM AS A MATERIAL HANDLING MATRIX METALOPROTEINASE
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
KR100419353B1 (en) * 1997-07-31 2004-02-19 아보트 러보러터리즈 N-Hydroxyformamide derivatives and a composition for inhibiting matrix metalloproteinases comprising the same

Also Published As

Publication number Publication date
DE69934094T2 (en) 2007-06-06
AU2291499A (en) 1999-08-16
CN100402496C (en) 2008-07-16
HK1029330A1 (en) 2001-03-30
JP2002501943A (en) 2002-01-22
NO20003868D0 (en) 2000-07-28
DK1051395T3 (en) 2007-04-02
NO326266B1 (en) 2008-10-27
NO20003868L (en) 2000-07-28
CA2317455C (en) 2011-01-25
ES2277424T3 (en) 2007-07-01
HUP0100597A3 (en) 2001-12-28
CA2317455A1 (en) 1999-08-05
ATE346041T1 (en) 2006-12-15
AU735929B2 (en) 2001-07-19
WO1999038843A1 (en) 1999-08-05
EP1051395A1 (en) 2000-11-15
CY1106338T1 (en) 2011-10-12
PL200418B1 (en) 2009-01-30
BR9908215A (en) 2000-11-28
PL342184A1 (en) 2001-05-21
HUP0100597A2 (en) 2001-08-28
US6100266A (en) 2000-08-08
CN1289322A (en) 2001-03-28
DE69934094D1 (en) 2007-01-04
EP1051395B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
IL137146A0 (en) Hydroxamic and carboxylic acid derivatives
EP1119362A4 (en) Method of using tetracycline compounds to enhance interleukin-10 production
PL314300A1 (en) Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases
FI971412A (en) Peptididyl compounds and their therapeutic use as inhibitors of metalloproteases
YU6602A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
CY1109328T1 (en) THIENODIBENZOAZULENIUM COMPOUNDS AS TUMOR NECROSION FACTOR INHIBITORS
EP0863757A4 (en)
NO20002440D0 (en) Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity
MY109722A (en) Azaoxindole derivatives.
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
BR0208694A (en) Use of selective cox-2 inhibitors to treat urinary incontinence
GB0003025D0 (en) Novel compounds
EA200200189A1 (en) APPLICATION OF INTERLEUKIN INHIBITORS 18
ATE247650T1 (en) HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
ATE394117T1 (en) USE OF CC CHEMOKINE CCL5/RANTES MUTANTS TO TREAT LIVER DISEASE
MX9706086A (en) Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition.
IT1294932B1 (en) USE OF SUBSTITUTED 2-AMINOTETHRALINE-6,7 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE TREATMENT OF PATHOLOGIES
MX9704729A (en) 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds.
MX9704740A (en) 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed